Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AIR-001 in adults with alpha-1 antitrypsin deficiency
NL-OMON61068Phase 1Not yet recruiting
- Sponsor
- AIRNA Pharmaceuticals
- Start
- Sep 2026
- Modality
- Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of AIR-001 in alpha-1 antitrypsin deficiency (AATD), sponsored by AIRNA Pharmaceuticals. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
AIR-001
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NL-OMON61068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61068.